First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$44.50 -4.87%

-$0.89 today

Market cap
$1.87B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.75M

Average 0.43M

TRAX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

First Tracks Biotherapeutics IncNASDAQ: TRAX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows 7.0% year over year

Q1 FY2026 net income of $50.48M (cash outflow) rose 7.0% year over year.

Context

  • Net income grew in size in 2 of the last 2 fiscal years.
  • FY2025 was the largest annual figure in the 3 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$50.48M— QoQ
Last fiscal yearDec 2025
-$166.09M+1.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.0%——
1 year+1.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Income history

USD · from the cash flow

Latest · FY2025
(166.09M) USD
Year-over-year change
-1.5%

Net Income vs competitors

How TRAX compares with its peers on the latest reported figures

  • TRAX's FY2025 net income of $166.09M is the 3rd largest of the 10 companies compared; the peer median is $71.75M.
  • Its year-over-year change of +1.5% is the 7th highest of 10, against a peer median of +9.5%.
TRAX Competitors Peer median
Net Income for TRAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$508.96M +9.5%+33.8%7173.5%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$259.47M +76.5%+66.1%—
TRAXFirst Tracks Biotherapeutics IncFY2025$166.09M +1.5%——
IMUXImmunic, Inc.LTM Mar 2026$104.29M +8.2%-6.9%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$78.15M +141.3%-19.7%—
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$71.75M +93.6%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M -46.5%-9.3%832.6%
ATTOAttovia Therapeutics, Inc.FY2025$60.9M +35.2%—4511.0%
CLYMClimb Bio, Inc.LTM Mar 2026$52.79M -43.2%+9.8%—
ANABAnaptysBio, Inc.LTM Mar 2026$26.79M -81.0%—11.5%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding TRAX) $71.75M+9.5%+1.4%2671.8%

Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(106.15M)(163.71M)(166.09M)
Depreciation & Amortization2.38M2.4M2.42M
Deferred Income Tax000
Stock-Based Compensation18.39M26.83M32.3M
Change in Working Capital2.9M18.99M(1.52M)
Accounts Receivables000
Inventory000
Accounts Payables8.39M17.81M0
Other Working Capital(5.49M)1.18M(1.52M)
Other Non-Cash Items(10.52M)(10.31M)(10.04M)
Operating Cash Flow(93M)(125.81M)(142.93M)
Capital Expenditures(807K)(358K)(87K)
Acquisitions (Net)000
Purchases of Investments(303.92M)(380.38M)0
Sales of Investments449.48M476.13M0
Other Investing Activities00228.12M
Investing Cash Flow144.75M95.4M228.03M
Debt Repayment000
Common Stock Issued0117.52M0
Common Stock Repurchased000
Dividends Paid000
Other Financing Activities0030.01M
Financing Cash Flow(87.09M)117.52M30.01M
Effect of Forex Changes000
Net Change in Cash(35.34M)87.12M115.12M
Free Cash Flow(93.81M)(126.16M)(143.01M)

First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Intrinsic Alpha fair value

Locked

Current Price

$44.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.